20. December 2011 13:04
Amgen’s Chairman and CEO, Kevin W. Sharer, will retire from the company at the end of next year after two decades of service at the pharmaceutical company.
Mr Sharer will step down as CEO in May 23rd 2012 but remain as Chairman until December 31st 2012 when he will leave the board and the company. Robert Bradway, current President and Chief Operating Officer, will succeed Mr Sharer as CEO.
Vance Coffman, Chairman of the Board’s Governance and Nominating Committee, says the departing Mr Sharer leaves the company “well positioned for the future”.
Executive Vice President of Research and Development, Roger Perlmutter, will also retire from his position on February 12th 2012. Dr Sean Harper will succeed him and report to the new CEO.
“Today Amgen announces its next generation of leaders as we pass the reins to Bob Bradway and Sean Harper,” said the out-going Kevin Sharer. “Amgen will be in good hands.”
Robert Bradway joined Amgen in 2006 as a vice president in operations. He was appointed CFO a year later and names President and Chief Operating Officer in 2010. He worked for Morgan Stanley for nearly two decades before joining the company.
Dr Harper joined in 2002 and has held leadership roles in early development, medical sciences and global regulatory and safety.